AXSM

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics (AXSM - Research Report), with a price target of $210.00. The company's shares opened today at $40.65.According to TipRanks, Selvaraju is an analyst with an average return of -33.5% and a 19.51% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Genmab, and Eton Pharmaceuticals.Axsome Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $87.80, implying an 115.99% upside from current levels. In a report released on October 14, Mizuho Securities also maintained a Buy rating on the stock with a $76.
https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-buy-rating-for-axsome-therapeutics-axsm?utm_source=advfn.com&utm_medium=referral